Hervé Affagard, MaaT Pharma CEO

August 11, 2022 07:16 AM EDT

One year into clinical hold, FDA has more questions about 'pooled' microbiome therapy

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: Trump administration reveals 'most favored nation' drug price country targets

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Why Regeneron is buying 23andMe

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?